Novo Nordisk Introduces $199 Monthly Self-Pay Offer for Wegovy® and Ozempic®

Novo Nordisk has unveiled a new self-pay pricing initiative for several of its popular medications, Wegovy® and Ozempic®, aimed at increasing accessibility for patients in the United States. Starting November 17, 2025, the first two doses for new self-pay patients will be available for $199 each, a significant reduction from the previous $499 monthly fee.

Details of the Pricing Offer

The limited-time offer will be in effect until March 31, 2026, and applies to the two lowest doses of both medications (0.25 mg and 0.5 mg). After the initial two-month period, the monthly cost for self-pay patients will be adjusted to $349.

Accessing the New Pricing

Patients can take advantage of this pricing through various channels:

• Over 70,000 pharmacies across the U.S.
• Home delivery services via NovoCare® Pharmacy
• Select telehealth providers, including organizations such as GoodRx and Costco

Novo Nordisk’s Commitment to Accessibility

These changes follow recent agreements with the U.S. Administration aimed at enhancing drug accessibility for patients battling obesity and other chronic conditions. Dave Moore, Executive Vice President of U.S. Operations at Novo Nordisk, emphasized the company’s dedication to making FDA-approved medications affordable and accessible.

Significance of Semaglutide

Semaglutide, the active ingredient in both Wegovy® and Ozempic®, has established itself as a critical treatment option for various chronic diseases. Wegovy® is specifically indicated for individuals suffering from obesity, while Ozempic® is primarily used to manage type 2 diabetes.

Wegovy® and Ozempic® Overview

Obesity affects nearly 40% of adults in the U.S., and type 2 diabetes has a substantial impact on over 28 million people. The introduction of this self-pay offer comes as a response to the pressing need for affordable medication options in managing these prevalent conditions.

Ongoing Support and Savings Programs

For patients with commercial insurance who qualify, Novo Nordisk continues to offer savings programs aiding those on Wegovy® or Ozempic®. Interested individuals can learn more about costs and coverage by visiting NovoCare.com.

This strategic pricing initiative is part of Novo Nordisk’s broader efforts to expand access to its semaglutide medicines, ensuring that more patients can get the treatments they need without resorting to unsafe alternatives. The company’s proactive measures highlight its commitment to public health and patient safety.